OHR Pharmaceutical, Inc. operates as a biotechnology company. Its product line includes Squalamine, an anti-angiogenic small molecule with a novel intracellular mechanism of action that inhibits vascular endothelial, platelet derived, and basic fibroblast growth factors for the treatment of the wet form of age-related macular degeneration using an eye drop formulation. The company also offers OHR/AVR 118, a Phase IIa clinical trial product for the treatment of cancer cachexia. In addition, it owns various other compounds in earlier stages of development, including the PTP1b inhibitor trodusquemine and related analogs, which are in preclinical research stage. The company is headquartered in New York, New York.
Address
28th Floor, 489 5th Avenue
NEW YORK, NY 10017
United States
NEW YORK, NY 10017
United States
Website
http://www.ohrpharmaceutical.comKey stats and ratios
| Q3 (Sep '13) | 2013 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -114.77% | -122.07% |
| Return on average equity | -121.86% | -147.01% |
| Employees | 2 |
No comments:
Post a Comment